MX2023002161A - Composiciones y metodos para enfermedades neurologicas. - Google Patents

Composiciones y metodos para enfermedades neurologicas.

Info

Publication number
MX2023002161A
MX2023002161A MX2023002161A MX2023002161A MX2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A
Authority
MX
Mexico
Prior art keywords
compositions
methods
neurological diseases
engineered receptors
modulating
Prior art date
Application number
MX2023002161A
Other languages
English (en)
Spanish (es)
Inventor
Stefanie Makinson
Jr Anthony Lau
Jr Orion P Keifer
Alexander Naka
Original Assignee
Trames Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trames Bio Inc filed Critical Trames Bio Inc
Publication of MX2023002161A publication Critical patent/MX2023002161A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023002161A 2020-08-21 2021-08-20 Composiciones y metodos para enfermedades neurologicas. MX2023002161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068890P 2020-08-21 2020-08-21
PCT/US2021/046915 WO2022040535A2 (en) 2020-08-21 2021-08-20 Compositions and methods for neurological diseases

Publications (1)

Publication Number Publication Date
MX2023002161A true MX2023002161A (es) 2023-05-18

Family

ID=80350587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002161A MX2023002161A (es) 2020-08-21 2021-08-20 Composiciones y metodos para enfermedades neurologicas.

Country Status (11)

Country Link
US (1) US20240317834A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200020A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023538130A (cg-RX-API-DMAC7.html)
KR (1) KR20230061409A (cg-RX-API-DMAC7.html)
CN (1) CN116802201A (cg-RX-API-DMAC7.html)
AU (1) AU2021329529A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003167A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192604A1 (cg-RX-API-DMAC7.html)
IL (1) IL300816A (cg-RX-API-DMAC7.html)
MX (1) MX2023002161A (cg-RX-API-DMAC7.html)
WO (1) WO2022040535A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487904B (zh) * 2023-12-28 2024-05-31 湖南家辉生物技术有限公司 Gabrb3基因突变体、突变体蛋白、试剂、试剂盒及应用
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311984A (en) * 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
IL274702B2 (en) * 2017-11-27 2026-04-01 Coda Biotherapeutics Inc Compounds and methods for neurological diseases
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法

Also Published As

Publication number Publication date
US20240317834A1 (en) 2024-09-26
IL300816A (en) 2023-04-01
BR112023003167A2 (pt) 2023-05-02
JP2026082870A (ja) 2026-05-19
WO2022040535A2 (en) 2022-02-24
WO2022040535A3 (en) 2022-03-31
EP4200020A4 (en) 2024-11-20
AU2021329529A1 (en) 2023-04-27
EP4200020A2 (en) 2023-06-28
JP2023538130A (ja) 2023-09-06
CA3192604A1 (en) 2022-02-24
AU2021329529A9 (en) 2025-03-13
KR20230061409A (ko) 2023-05-08
CN116802201A (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
ZA202408862B (en) Compositions and methods for neurological diseases
Muir et al. Recent advances in the therapeutic uses of chondroitinase ABC
Levin et al. The bioelectric code: An ancient computational medium for dynamic control of growth and form
Choi et al. Epidural electrical stimulation for spinal cord injury
WO2009033027A3 (en) Suppression of scn9a gene expression and/or function for the treatment of pain
Grefkes et al. Noninvasive brain stimulation after stroke: it is time for large randomized controlled trials!
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
WO2022040535A3 (en) Compositions and methods for neurological diseases
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
DE602004020061D1 (de) Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
WO2022195074A3 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MY168084A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
Manser-Smith et al. A common representation of fingers and toes
WO2023159208A3 (en) Compositions and methods for neurological diseases
MX2021013351A (es) Terapias de combinacion.
Zhang et al. Analysis of the effect of combined rehabilitation training and transcutaneous vagus nerve electrical stimulation on promoting central nervous system remodeling in stroke patients
BR112019003912A2 (pt) composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo
Liu et al. Theory-driven EEG indexes for tracking motor recovery and predicting the effects of hybridizing tDCS with mirror therapy in stroke patients
Gupta et al. Transcranial magnetic stimulation therapy in spastic cerebral palsy children improves motor activity